亚太地区眼部药物输送市场预测至 2028 年 - COVID-19 影响和区域技术分析（植入式眼部药物输送系统、颗粒药物输送系统、纳米颗粒药物输送系统等）、制剂类型（脂质体和纳米颗粒、解决方案） 、乳剂、混悬剂和软膏）、疾病类型（青光眼、糖尿病视网膜病变、干眼综合症、黄斑变性、白内障、糖尿病黄斑水肿等）和最终用户（医院、眼科诊所和门诊手术中心）
No. of Pages: 145 | Report Code: TIPRE00025781 | Category: Life Sciences
No. of Pages: 145 | Report Code: TIPRE00025781 | Category: Life Sciences
亚太地区由中国、日本、印度、澳大利亚和韩国五个主要国家组成。还对亚太地区其他国家的市场进行了评估。日本在亚太地区眼部给药市场中占有最大份额。在日本，正常眼压性青光眼（NTG）（青光眼的一种形式）的发病率大幅增加或更高。青光眼的患病率主要见于老年人群；截至 2017 年，日本有近 400 万人登记患有青光眼。该国改进了青光眼治疗方案。这一改进为全国各地的患者引入了新的抗青光眼眼科解决方案和微创青光眼手术。同样，该国也有相当数量的干眼病（DED）患者，该国针对干眼病进行了各种研究。研究结果显示，日本人中DED的患病率相对较高。该国每位患者的年度健康计划费用估计接近 323 美元。此外，该国糖尿病患者数量不断增加，这是糖尿病视网膜病变的另一个主要原因。在日本总人口中，约 720 万成年人患有糖尿病，占近 7.7%。该国面临着眼科医生数量不断减少的问题。然而，就医疗基础设施的发展而言，该国是重要国家之一。
2019 年新型冠状病毒（2019-nCoV）被世界卫生组织正式命名为 COVID-19，已传播到超过包括中国在内的 170 个国家促使世界卫生组织宣布该疾病为全球大流行病。 COVID-19 对整个亚太地区的眼保健服务产生了巨大影响。在孟加拉国，所有常规选择性眼科手术均被推迟。仅在门诊进行紧急眼科治疗。此外，只有在紧急情况下才允许患者去医院。同样，在印度，外展眼保健服务大部分停止，从而影响了农村社区。所有择期手术均被推迟。糖尿病视网膜病变和青光眼等非白内障患者因随访中断而受到影响。此外，COVID-19 对马尔代夫的眼保健产生了巨大影响。由于封锁，人们无法从一个地方前往另一个地方。空运和海运均处于停滞状态，离岛民众无法前往最近的眼科护理中心。首都马累的一些中心正在为患者提供在线咨询。然而，这有其局限性，医疗保健专业人员无法在线进行验光，也无法进行详细的眼前节和后节检查。因此，COVID 19 对马尔代夫眼科护理的质量和数量产生了重大影响。
亚太地区眼科给药市场预计将从 2021 年的 32.3493 亿美元增长到 2028 年的 56.0856 亿美元。预计 2021 年至 2028 年该市场的复合年增长率为 8.2%。白内障、青光眼、年龄相关性黄斑变性、糖尿病性视网膜病变和未解决的屈光不正是失明或低视力的主要原因。大多数人一生中都患有或患有某种眼部疾病。根据世界卫生组织 (WHO) 2021 年 2 月发布的报告《失明和视力障碍》，全球约有 22 亿人存在近视力或远视力障碍。据估计，视力丧失或低视力的主要原因是白内障（9400万）和未矫正的屈光不正（8840万）。此外，视力丧失的其他常见原因包括青光眼（770 万）、角膜混浊（420 万）、糖尿病性视网膜病变（390 万）和沙眼（200 万）。因此，眼部疾病的迅速流行可能会促进市场的增长。
亚洲太平洋眼部药物输送市场根据技术、制剂类型、疾病类型、最终用户进行细分。按技术划分，2021年植入式眼部给药系统份额最高。按剂型划分，2021年溶液细分市场份额最高。按疾病类型划分，2021年白内障细分市场份额最高。终端用户医院细分市场在 2021 年占据最高份额。
一些主要的初级和准备本亚太地区眼部药物输送市场报告时参考的二手来源包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司有艾伯维公司（AbbVie Inc.）；博士健康公司；诺华公司； Clearside 生物医学公司；和台湾脂质体股份有限公司等等。
Strategic insights for Asia Pacific Ocular Drug Delivery involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 3,234.93 Million |
| Market Size by 2028 | US$ 5,608.56 Million |
| Global CAGR (2021 - 2028) | 8.2% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 技术
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Ocular Drug Delivery refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Ocular Drug Delivery Market is valued at US$ 3,234.93 Million in 2021, it is projected to reach US$ 5,608.56 Million by 2028.
As per our report Asia Pacific Ocular Drug Delivery Market, the market size is valued at US$ 3,234.93 Million in 2021, projecting it to reach US$ 5,608.56 Million by 2028. This translates to a CAGR of approximately 8.2% during the forecast period.
The Asia Pacific Ocular Drug Delivery Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Ocular Drug Delivery Market report:
The Asia Pacific Ocular Drug Delivery Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Ocular Drug Delivery Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Ocular Drug Delivery Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Ocular Drug Delivery Market
